Wolverine Asset Management LLC Has $1.12 Million Holdings in Insulet Co. (NASDAQ:PODD)

Wolverine Asset Management LLC cut its holdings in Insulet Co. (NASDAQ:PODD) by 99.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 5,163 shares of the medical instruments supplier’s stock after selling 1,495,237 shares during the quarter. Wolverine Asset Management LLC’s holdings in Insulet were worth $1,120,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PODD. GAMMA Investing LLC bought a new stake in Insulet during the fourth quarter worth $55,000. Linden Thomas Advisory Services LLC raised its position in Insulet by 1.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock worth $1,262,000 after acquiring an additional 73 shares in the last quarter. Jennison Associates LLC raised its position in Insulet by 57.7% during the fourth quarter. Jennison Associates LLC now owns 207,519 shares of the medical instruments supplier’s stock worth $45,027,000 after acquiring an additional 75,954 shares in the last quarter. Duality Advisers LP raised its position in Insulet by 15.9% during the fourth quarter. Duality Advisers LP now owns 10,102 shares of the medical instruments supplier’s stock worth $2,192,000 after acquiring an additional 1,387 shares in the last quarter. Finally, EFG Asset Management Americas Corp. raised its position in shares of Insulet by 7.9% in the fourth quarter. EFG Asset Management Americas Corp. now owns 9,180 shares of the medical instruments supplier’s stock valued at $1,992,000 after purchasing an additional 669 shares during the period.

Insiders Place Their Bets

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

PODD has been the topic of several research analyst reports. Piper Sandler dropped their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Barclays lowered their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Stifel Nicolaus raised their price target on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.21.

Insulet Stock Performance

NASDAQ PODD opened at $164.17 on Friday. The company has a fifty day simple moving average of $172.00 and a 200 day simple moving average of $179.25. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $335.91. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86. The company has a market cap of $11.50 billion, a P/E ratio of 56.42, a PEG ratio of 3.01 and a beta of 0.98.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. The business had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. Insulet’s revenue was up 37.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.55 EPS. Sell-side analysts predict that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.